诚意药业四款产品拟中选国家集采接续采购

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. announced participation in the national organized procurement for the first to eighth batches, with four products proposed for selection, covering a procurement period until December 31, 2028 [1] Group 1: Procurement Details - The four products proposed for selection are Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection [1] - The procurement is organized by a coalition of provinces and the Xinjiang Production and Construction Corps, with Jiangsu, Henan, and Guangdong provinces leading the unified national procurement [1] - Selected drugs will be prioritized for use by medical institutions, ensuring the completion of the agreed procurement volume [1] Group 2: Financial Impact - Glucosamine Hydrochloride Capsules are the company's main product, projected to generate revenue of 335 million yuan in 2024, accounting for 46.88% of total revenue [1] - For the first three quarters of 2025, revenue from Glucosamine Hydrochloride Capsules is expected to reach 345 million yuan, representing 57.85% of total revenue [1] - The other three products have relatively smaller revenue contributions [1] Group 3: Uncertainties and Risks - The final results of the proposed selections remain uncertain, and relevant procurement contracts have yet to be signed [1] - The quantity of selected products is not clearly defined, and production and sales are subject to policy and market environment influences [1]